Anticoagulation for HCM with Atrial Fibrillation
Direct oral anticoagulants (DOACs) are the first-line anticoagulation choice for patients with hypertrophic cardiomyopathy and atrial fibrillation, with warfarin as the second-line option, and this recommendation applies regardless of CHA2DS2-VASc score. 1
Primary Recommendation
The 2024 AHA/ACC/HRS guideline provides a Class I, Level B-NR recommendation that all patients with HCM and clinical AF should receive anticoagulation with DOACs as first-line therapy and vitamin K antagonists (warfarin) as second-line 1. This is a universal recommendation—you do not calculate or use the CHA2DS2-VASc score in HCM patients because traditional stroke risk scoring systems fail to predict thromboembolic events in this population 1, 2.
Why DOACs Over Warfarin?
Recent high-quality evidence strongly supports DOAC superiority:
The 2026 retrospective cohort study of 7,090 DOAC vs 3,350 warfarin patients (after propensity matching: 3,307 each) demonstrated that DOACs reduced ischemic stroke by 26% (HR 0.74,95% CI: 0.58-0.95) and decreased all-cause hospitalization (HR 0.90) compared to warfarin, with similar mortality and no significant difference in bleeding complications 3
A 2025 Japanese real-world study of 2,955 DOAC vs 1,603 warfarin patients showed DOACs reduced stroke/systemic embolism by 33% (HR 0.67,95% CI: 0.47-0.96) with comparable bleeding risk 4
Meta-analysis of 6,919 patients confirmed DOACs significantly reduced all-cause mortality (HR 0.64, p<0.00001) with comparable major bleeding and thromboembolic events 5
Subclinical AF Detection
For subclinical AF detected by cardiac devices:
- ≥24 hours duration: Anticoagulate with DOACs (Class I recommendation) 1
- 5 minutes to <24 hours duration: Consider anticoagulation with DOACs (Class IIa recommendation), weighing AF burden, duration, risk factors, and bleeding risk 1
This is critical because asymptomatic AF episodes carry substantial stroke risk in HCM patients.
Common Pitfalls to Avoid
Do NOT use CHA2DS2-VASc scoring in HCM—patients with low scores still have substantial stroke risk due to disease-specific prothrombotic mechanisms 1, 2, 6
Do NOT delay anticoagulation after the first AF episode—stroke risk is immediate and substantial in HCM 2
Do NOT withhold anticoagulation based on paroxysmal vs persistent AF classification—both require anticoagulation in HCM 1
Rate Control Agents
When rate control is the chosen strategy, use beta-blockers, verapamil, or diltiazem based on patient comorbidities and preferences (Class I recommendation) 1. These agents also help manage LVOT obstruction symptoms common in HCM.
Clinical Context
AF occurs in nearly 50% of HCM patients over their lifetime and represents a major driver of morbidity 2. The structural and functional abnormalities in HCM—including atrial enlargement, diastolic dysfunction, and myocardial fibrosis—create a uniquely high-risk substrate for thromboembolism that operates independently of traditional AF risk factors 7, 6.